Morphotek Inc.
210 Welsh Pool Road
Exton
Pennsylvania
19341
United States
Tel: 610-423-6100
Website: http://www.morphotek.com/
Email: nfo@morphotek.com
110 articles about Morphotek Inc.
-
Tmunity Appoints Christina Coughlin, MD, PhD, as Chief Medical Officer and Executive Vice President
7/10/2018
Tmunity Therapeutics, Inc. today announced the appointment of Christina Coughlin, MD, PhD, as Chief Medical Officer and Executive Vice President.
-
Morphotek Announces Agreement to License its Proprietary Eribulin-Linker Payload to Bliss Biopharmaceutical Co., Ltd. for Development of a Therapeutic Antibody-Drug Conjugate (ADC)*
4/9/2018
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it licensed its eribulin-linker payload to Bliss Biopharmaceutical Co., Ltd. (BlissBio) of China.
-
Morphotek Announces FDA Acceptance of IND Application For Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202
1/10/2018
A Phase 1 dose-escalation study will be conducted in the U.S. to evaluate the safety and preliminary efficacy of MORAb-202 in patients with solid tumors that express FRA.
-
Morphotek and Rockefeller University Form a Sponsored Research Agreement to Study the Immunosuppressive Effects of the Tumor Shed Antigen CA125 and its Potential Impact in Future Patient Therapies
12/11/2017
The research will focus on expanding the knowledge of how CA125 suppresses humoral immune responses to antibody-mediated therapies via these two mechanisms.
-
Morphotek Announces Initiation of Phase I Study of Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202 in Solid Tumors With Folate Receptor Alpha Expression
12/4/2017
The Phase I trial, which is being conducted in Japan and referred to as MORAb-202-J081-101, is a first-in-human, dose-escalation study evaluating the safety and preliminary efficacy of MORAb-202 in patients with solid tumors that express FRA.
-
Morphotek Announces Collaboration Agreement With The Johns Hopkins University To Research And Develop Novel Monoclonal Antibody-Based Therapies Targeting Missplicing-Associated Surface Antigens
9/6/2017
-
Morphotek Announces An Agreement With Fujirebio Diagnostics, Inc. To Commercialize The CA125 II Assay As A Companion Diagnostic For Farletuzumab
9/5/2017
-
Morphotek Announces Publication Uncovering One Of The Mechanisms By Which The Tumor-Produced CA125 Protein Suppresses Immune-Mediated Killing Via Farletuzumab
7/11/2017
-
Morphotek Launches Antibody Drug Conjugate Services Business
4/3/2017
-
Morphotek And Sandy Rollman Ovarian Cancer Foundation Launch Educational Resource On Clinical Trials
3/22/2017
-
Morphotek And Eurofarma Laboratórios S.A. Sign Exclusive Licensing Agreement For Farletuzumab In Latin America
10/3/2016
-
Morphotek Announces Sponsored Research Agreement With Fox Chase Cancer Center To Study Immunosuppressive Effects Of Tumor Shed Antigens To Improve Future Patient Therapies
9/13/2016
-
Morphotek Announces Publication Of Phase 3 Results From Morab-003-004 Trial In Platinum-Sensitive Ovarian Cancer Patients
4/18/2016
-
As part of Eisai Company’s Strategic Plan, Morphotek Subsidiary Cuts 27 Jobs as Part of Restructuring
3/23/2016
-
Morphotek Inc. Announces Collaboration With Mayo Clinic To Apply Its Folate Receptor Alpha Diagnostic Assays In A Phase II Clinical Trial In Triple-Negative Breast Cancer
2/3/2016
-
CryoPort, Inc. Is Selected By Morphotek Inc. To Manage Cold Chain Logistics
1/14/2016
-
Morphotek Inc. Announces An Agreement With BioCare Medical To Develop And Commercialize A Diagnostic Kit For Detection Of Mesothelin In Malignant Tissues
12/16/2015
-
Morphotek Inc. Announces Phase 1 Results From MORAb-022-001 Trial In Healthy Subjects And Patients With Mild-To-Moderate Rheumatoid Arthritis
12/7/2015
-
Morphotek Inc. Announces Collaboration Agreement With University of Wisconsin-Madison To Study The Immunosuppressive Effects Of Ca125 Tumor Antigen On Immune-Based Therapies For Ovarian Cancer
12/3/2015
-
Morphotek Inc. Announces Initiation Of Amatuximab Study In First-Line, Unresectable, Malignant Pleural Mesothelioma Patients
11/18/2015